Symptomatic creatine phosphokinase elevation in a Crohn's disease patient caused by upadacitinib
Open Access
- 19 January 2024
- journal article
- research article
- Published by Wiley in Clinical Case Reports
- Vol. 12 (1) , e8227
Abstract
Key Clinical Message: We present a Crohn's disease patient receiving high dose upadacitinib treatment with elevated CPK levels and myopathy, and provide the reader with practical tips on stopping and restarting upadacitinib, emphasizing the need for adequate monitoring.Keywords
This publication has 6 references indexed in Scilit:
- Upadacitinib Induction and Maintenance Therapy for Crohn’s DiseaseNew England Journal of Medicine, 2023
- Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitisRMD Open, 2023
- A Comprehensive Overview of Globally Approved JAK InhibitorsPharmaceutics, 2022
- Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s DiseaseGastroenterology, 2020
- Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinibClinical Rheumatology, 2019
- Asymptomatic/pauci‐symptomatic creatine kinase elevations (hyperckemia)Muscle & Nerve, 2013